Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial.
Toshihiro KitaShinya AshizukaTeruyuki TakedaTakayuki MatsumotoNaoki OhmiyaHiroshi NakaseSatoshi MotoyaHidehisa OhiKeiichi MitsuyamaTadakazu HisamatsuShuji KanmuraNaoya KatoShunji IshiharaMasanao NakamuraTomohiko MoriyamaMasayuki SarutaRyoichi NozakiShojiro YamamotoHaruhiko InatsuKoji WatanabeKazuo KitamuraPublished in: Journal of gastroenterology and hepatology (2022)
In this trial, we observed a long-lasting (24 weeks) decrease in CDAI in the adrenomedullin-treated groups. Adrenomedullin might be beneficial for biologic-resistant CD, but further research is needed.